Sugammadex Aguettant: Uses, Dosage & Side Effects
Selective Relaxant Binding Agent — Rapid reversal of rocuronium and vecuronium neuromuscular blockade
Quick Facts About Sugammadex Aguettant
Key Takeaways About Sugammadex Aguettant
- Reverses muscle paralysis in minutes: Sugammadex Aguettant rapidly reverses the neuromuscular blocking effects of rocuronium and vecuronium, typically restoring full muscle function within 2 to 3 minutes, even from very deep blockade
- Generic equivalent of Bridion: Sugammadex Aguettant contains the same active ingredient (sugammadex) at the same concentration (100 mg/ml) as the originator product Bridion, manufactured by Laboratoire Aguettant and approved through EMA bioequivalence review
- Given only by anesthesia professionals: It is administered as a single intravenous injection, with dose individualized by weight and depth of neuromuscular block, ideally guided by a quantitative neuromuscular monitor
- Reduces contraceptive effectiveness: A single dose is considered equivalent to missing one daily dose of an oral contraceptive — additional non-hormonal contraception is required for 7 days
- Avoid re-using rocuronium for 24 hours: After sugammadex, further rocuronium or vecuronium should not be given within 24 hours (or longer in renal impairment) because residual sugammadex will neutralize the relaxant
What Is Sugammadex Aguettant and What Is It Used For?
Sugammadex Aguettant is an intravenous medicine used in general anesthesia to rapidly reverse the muscle paralysis caused by the neuromuscular blocking drugs rocuronium and vecuronium. It works by chemically encapsulating these drugs in the bloodstream so that they can no longer act on the muscles. This allows patients to resume spontaneous breathing and normal muscle strength within a few minutes after surgery or an emergency intubation.
Sugammadex Aguettant is a prescription-only injectable solution manufactured by Laboratoire Aguettant, a French pharmaceutical company specializing in hospital and emergency medicines. It contains sugammadex sodium as its active ingredient at a concentration of 100 mg/ml, supplied in ready-to-use pre-filled syringes designed to minimize preparation time in the operating theatre, emergency department, and intensive care unit. The product has been approved in the European Union through the hybrid application procedure, demonstrating pharmaceutical equivalence and therapeutic bioequivalence to the originator medicine Bridion.
During general anesthesia, anesthesiologists frequently administer neuromuscular blocking agents — sometimes called "muscle relaxants" — to paralyze the voluntary muscles. This facilitates endotracheal intubation, allows controlled mechanical ventilation, and provides the surgeon with optimal operating conditions by keeping the patient completely still. Rocuronium and vecuronium are two of the most widely used steroidal (aminosteroid) neuromuscular blockers, valued for their predictable onset, reliable duration, and cardiovascular stability. However, at the end of surgery, any residual paralysis must be reversed before the patient can safely breathe on their own and be extubated.
Traditional reversal of rocuronium or vecuronium has relied on acetylcholinesterase inhibitors such as neostigmine, usually combined with an anticholinergic (glycopyrrolate or atropine) to counteract muscarinic side effects. While effective in mild to moderate residual blockade, neostigmine is limited: it cannot be used until some neuromuscular recovery has already occurred (typically a train-of-four ratio above 0.2 to 0.4), it has a relatively slow onset of 7 to 10 minutes, and it carries the risk of bradycardia, bronchoconstriction, increased salivation, postoperative nausea and vomiting, and paradoxical muscle weakness at excessive doses. These limitations contributed to a significant clinical problem — residual neuromuscular blockade in the recovery room, which is associated with respiratory complications, atelectasis, aspiration, and prolonged hospital stay.
Sugammadex was developed to solve this problem. Unlike neostigmine, sugammadex works by a completely different mechanism: physical encapsulation. The molecule is a modified gamma-cyclodextrin — a doughnut-shaped sugar derivative with a hydrophobic cavity and a hydrophilic exterior. The cavity is precisely shaped to fit the rigid steroid framework of rocuronium and, to a lesser extent, vecuronium, forming an ultra-stable 1:1 host-guest complex with a dissociation constant on the order of 10 nM. Once a rocuronium molecule is captured by sugammadex, it can no longer bind to the nicotinic acetylcholine receptors at the neuromuscular junction and is rapidly cleared from the body by renal excretion.
Approved Indications
Sugammadex Aguettant is approved in adults and in children from two years of age for the following indications:
- Routine reversal of neuromuscular blockade induced by rocuronium or vecuronium: In adults and pediatric patients aged 2 years and older, at the end of surgery when the train-of-four (TOF) response indicates moderate to deep residual blockade
- Immediate reversal after a single intubating dose of rocuronium in adults: For example, in "cannot intubate, cannot ventilate" situations or when surgery has to be abandoned shortly after induction of anesthesia. In this setting a higher dose (16 mg/kg) is used
Sugammadex is a cyclic oligosaccharide based on a modified gamma-cyclodextrin scaffold. Its three-dimensional structure forms a lipophilic cavity that precisely accommodates the D-ring of the steroid nucleus of rocuronium, creating a very tight 1:1 inclusion complex. Because the complex cannot cross the neuromuscular junction and is quickly eliminated through the kidneys, free rocuronium concentrations in plasma and at the motor endplate fall rapidly. This reverses neuromuscular blockade regardless of its depth — a pharmacological property that was not achievable with previous reversal strategies. Sugammadex has no intrinsic pharmacological activity on acetylcholinesterase, acetylcholine receptors, or the autonomic nervous system.
Hybrid (Generic) Equivalence and Quality Assurance
Sugammadex Aguettant was approved through a hybrid regulatory pathway, meaning that pharmaceutical and therapeutic equivalence to the reference product Bridion has been demonstrated through appropriate in vitro and in vivo studies. Because sugammadex is an intravenous molecule with well-characterized pharmacokinetics, the demonstration typically focuses on identical active ingredient, strength, dosage form, route of administration, and manufacturing standards. Aguettant produces the product at facilities compliant with European Union Good Manufacturing Practice (EU-GMP) standards, under ongoing inspection by the French National Agency for Medicines and Health Products Safety (ANSM).
For anesthesia services, the availability of a clinically equivalent sugammadex at a potentially lower acquisition cost has significant implications for resource planning, particularly in countries where routine use of quantitative neuromuscular monitoring and sugammadex has become the new standard of care. Studies in European hospitals have documented that substitution between sugammadex brands produces identical pharmacodynamic outcomes, provided that the correct dose is calculated using actual body weight and monitored depth of blockade.
Place in Modern Anesthesia Practice
International perioperative guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC) and the American Society of Anesthesiologists (ASA) now recommend the routine use of quantitative neuromuscular monitoring whenever neuromuscular blockers are administered, with pharmacological reversal of residual block before extubation. Sugammadex is the reversal agent of choice after rocuronium or vecuronium, especially in patients with higher risk of pulmonary complications, obesity, obstructive sleep apnea, deep block at the end of surgery, or when rapid and complete recovery is essential.
What Should You Know Before Taking Sugammadex Aguettant?
Because sugammadex is given intravenously only during anesthesia care, your anesthesiologist will assess you before surgery to identify any contraindications, drug interactions, and special conditions that might change the dose or the choice of reversal strategy. Key considerations include allergy history, kidney function, cardiac conduction, pregnancy status, and concurrent medicines such as hormonal contraceptives and toremifene.
Sugammadex has an overall favorable safety profile when used as recommended. However, like all medicines administered in the perioperative setting, it requires a systematic assessment of patient-specific risk factors and a willingness to adjust or withhold the drug when indicated. The preoperative evaluation performed by the anesthesiologist is the main opportunity to identify these factors. Patients and their caregivers can contribute by providing a complete medical history including prior reactions to anesthesia, all current medicines (including over-the-counter drugs, herbal products, and contraceptives), and known allergies.
Contraindications
Sugammadex Aguettant must not be used in the following situations:
- Hypersensitivity to sugammadex or any of the excipients: Patients with a documented severe hypersensitivity reaction (including anaphylaxis) to a previous dose of sugammadex must not receive the drug again
- Clinically significant renal insufficiency: Sugammadex Aguettant is not recommended in patients with creatinine clearance below 30 ml/min or in those requiring dialysis, because sugammadex and the sugammadex-rocuronium complex are eliminated almost entirely by the kidneys and may accumulate
Warnings and Precautions
Several clinical scenarios require particular attention:
Hypersensitivity and anaphylaxis. Hypersensitivity reactions to sugammadex have been reported in both previously exposed and sugammadex-naive patients. These reactions range from isolated skin rash to life-threatening anaphylaxis with hypotension, bronchospasm, angioedema, and cardiovascular collapse. The incidence appears to be dose-related and is higher with the 16 mg/kg dose than with smaller doses. All anesthetic workstations where sugammadex is used must be prepared to diagnose and treat anaphylaxis according to current resuscitation guidelines, including immediate access to epinephrine, intravenous fluids, and advanced airway support.
Marked bradycardia. Episodes of profound bradycardia, sometimes progressing to cardiac arrest, have been reported within minutes after sugammadex administration. The mechanism is not fully understood but is thought to involve rapid changes in autonomic balance as neuromuscular function recovers. The anesthesia team must monitor heart rate and hemodynamics continuously during and after injection and be prepared to treat bradycardia with atropine, glycopyrrolate, or epinephrine as clinically indicated.
Recurrence of neuromuscular block. An inadequate dose of sugammadex, particularly in patients with deep block or obesity, can lead to incomplete or transient reversal followed by re-paralysis when plasma sugammadex levels fall. This has been described up to 15 minutes after injection. The risk is minimized by using the correct weight-based dose guided by quantitative neuromuscular monitoring, and by continuing to monitor the train-of-four ratio until full recovery (TOF ratio ≥ 0.9) is confirmed.
Prolonged neuromuscular recovery in renal impairment. In mild to moderate renal impairment (creatinine clearance 30–80 ml/min), elimination of the sugammadex-rocuronium complex is slower, which may prolong the interval before rocuronium can safely be re-administered. In severe renal impairment, the drug is not recommended.
Impact on coagulation tests. High doses of sugammadex may transiently prolong activated partial thromboplastin time (aPTT) and prothrombin time (PT/INR) for up to 1 hour, although clinically significant bleeding has not been consistently demonstrated. Surgeons performing procedures associated with high bleeding risk should be aware of this effect and interpret coagulation tests taken in the first hour after sugammadex accordingly.
Pediatric population. Sugammadex is approved in children from 2 years of age at the doses of 2 mg/kg (for moderate block) and 4 mg/kg (for deep block). The 16 mg/kg dose for immediate reversal has not been sufficiently studied in children and is not recommended in this population.
Any rash, hives, facial or tongue swelling, wheezing, severe chest tightness, sudden drop in blood pressure, collapse, or extreme slowing of the heart rate that develops during or shortly after sugammadex administration should be considered a potential anaphylactic or cardiovascular emergency. Treatment must not be delayed: call for help, begin resuscitation, give epinephrine, and secure the airway. Document the reaction clearly in the medical record to protect future anesthesia care.
Pregnancy and Breastfeeding
There are limited clinical data on the use of sugammadex in pregnancy. Animal reproduction studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, but human data are insufficient to fully characterize the risk. Sugammadex Aguettant should be used during pregnancy only when the benefits to the mother clearly outweigh the potential risks to the fetus. In elective procedures during pregnancy, the anesthesiologist may consider alternative reversal strategies where appropriate.
It is not known whether sugammadex is excreted into human breast milk. Animal data suggest that excretion into milk is limited, and oral absorption of cyclodextrins is very low. Given the usually single-dose perioperative use and the minimal oral bioavailability, continued breastfeeding after a dose of sugammadex is generally considered acceptable. Women may express and discard milk for 12–24 hours after the dose if they wish to err on the side of caution, in line with local lactation-medicine guidance.
Effects on Hormonal Contraceptives
Sugammadex may reduce the effectiveness of hormonal contraceptives by binding progestogens, particularly when administered together with oral contraceptives. A single bolus of sugammadex is considered equivalent to missing one daily dose of a combined oral or progestogen-only contraceptive. Patients using any hormonal contraceptive method — including oral pills, patches, vaginal rings, subdermal implants, and progestogen-containing intrauterine devices — should follow the missed-dose instructions in their contraceptive's patient information leaflet and use an additional non-hormonal barrier method (such as condoms) for 7 days after receiving sugammadex.
Effects on Driving and Operating Machinery
Sugammadex itself does not impair cognitive function, but the procedure during which it is administered — typically general anesthesia — does. Patients should not drive, operate heavy machinery, make important legal decisions, or care for dependents alone for at least 24 hours after general anesthesia, in line with standard postoperative advice. They should arrange to be accompanied home by a responsible adult after day-case surgery.
How Does Sugammadex Aguettant Interact with Other Drugs?
Because sugammadex acts by binding specific molecules rather than by a metabolic enzyme pathway, classical pharmacokinetic interactions are uncommon. The most important interactions are capture-and-displacement interactions with other steroidal drugs such as rocuronium and vecuronium, and a clinically relevant reduction in the effect of hormonal contraceptives and toremifene. Fusidic acid may cause the opposite effect by displacing rocuronium from sugammadex and re-initiating neuromuscular blockade.
The unique encapsulation mechanism of sugammadex gives rise to a distinctive interaction profile. Instead of inducing or inhibiting cytochrome P450 enzymes or transporters, sugammadex behaves as a molecular "trap" that preferentially captures lipophilic steroidal molecules with the right dimensions. This has two practical consequences for anesthesia and perioperative care: first, other steroidal drugs or drugs that share structural features with the steroid nucleus may compete for binding; second, a substance with an especially strong affinity could theoretically displace rocuronium from sugammadex, freeing the relaxant to re-bind to the neuromuscular junction.
Major Interactions
The following combinations require active anesthesia management:
| Interacting Agent | Type of Interaction | Clinical Management |
|---|---|---|
| Rocuronium (re-administration) | Free sugammadex neutralizes newly injected rocuronium, reducing or abolishing its effect for up to 24 hours | Avoid re-using rocuronium within 24 h; use a non-steroidal relaxant (e.g. cisatracurium) or succinylcholine if blockade is urgently needed |
| Vecuronium (re-administration) | Same capture interaction as with rocuronium; vecuronium may be ineffective | Avoid within 24 h; choose a different class of neuromuscular blocker |
| Hormonal contraceptives | Sugammadex binds the progestogen component, reducing systemic availability; equivalent to one missed dose | Follow contraceptive leaflet for missed-dose advice and use additional non-hormonal contraception for 7 days |
| Toremifene | Toremifene may compete with rocuronium for binding to sugammadex, potentially slowing recovery | Monitor neuromuscular function closely and anticipate a prolonged reversal time in patients on toremifene |
| Fusidic acid (intravenous) | Fusidic acid may displace rocuronium from sugammadex after encapsulation, causing re-curarization | Avoid IV fusidic acid in the immediate postoperative period after sugammadex or monitor closely for recurrence of block |
Minor Interactions
Several other clinical situations have been reported or theorized, though their clinical significance is limited:
- Corticosteroids at anesthetic doses: High-dose steroids such as methylprednisolone, hydrocortisone, or dexamethasone do not meaningfully interfere with sugammadex at usual clinical exposures, but extreme combinations have been described in case reports
- Flucloxacillin and other small-molecule steroidal antibiotics: Theoretical concern about displacement, without evidence of clinical problems at standard doses
- Coagulation tests: Transient prolongation of aPTT and PT/INR for up to 1 hour after high-dose sugammadex; not a true drug interaction but relevant in surgery with bleeding risk
- Volatile anesthetics and total intravenous anesthesia: Sugammadex is fully compatible with sevoflurane, desflurane, isoflurane, propofol, and opioids; no dose adjustment is required
When considering re-paralysis after sugammadex, document the time and dose of sugammadex clearly on the anesthesia record. If the surgical or intensive care team subsequently needs neuromuscular blockade, a non-steroidal relaxant (cisatracurium or atracurium, both benzylisoquinoliniums) avoids the capture interaction. Succinylcholine can also be used for a short-duration block. If rocuronium is truly the only option, a significantly larger dose — often at least 1.2 mg/kg — combined with quantitative neuromuscular monitoring is required.
What Is the Correct Dosage of Sugammadex Aguettant?
Sugammadex Aguettant is dosed by actual body weight and by the depth of neuromuscular block at the time of reversal. The standard doses are 2 mg/kg for moderate block (reappearance of the second twitch of the train-of-four, T2) and 4 mg/kg for deep block (post-tetanic count of 1–2 with no T2 response). A higher dose of 16 mg/kg is used for immediate reversal in adults after a single intubating dose of rocuronium. The drug is always given as a single intravenous injection over 10 seconds, directly into a free-flowing intravenous line.
Sugammadex is one of the few anesthesia drugs where dosing is primarily determined by pharmacodynamic monitoring rather than fixed milligram-per-kilogram schedules. The key variable is the depth of neuromuscular block at the moment of reversal, assessed using a peripheral nerve stimulator at the adductor pollicis (thumb) or a quantitative monitor such as accelerography, electromyography, or kinemyography. Dose individualization based on quantitative monitoring significantly reduces the risk of both under-dosing (which would leave residual block) and unnecessary over-dosing (which increases cost and potential adverse effects).
Adults
Moderate block (T2 reappeared)
Recommended dose: 2 mg/kg intravenously. Recovery to TOF ratio ≥ 0.9 typically within 2–3 minutes. Suitable for the great majority of routine reversals at the end of surgery.
Deep block (post-tetanic count 1–2, no T2)
Recommended dose: 4 mg/kg intravenously. Recovery to TOF ratio ≥ 0.9 typically within 3 minutes. Used when surgery requires deep blockade close to emergence.
Immediate reversal after a single intubating dose of rocuronium
Recommended dose: 16 mg/kg intravenously, given approximately 3 minutes after a rocuronium dose of 1.2 mg/kg. Used in "cannot intubate, cannot ventilate" scenarios or when surgery is abandoned very early. Full neuromuscular recovery occurs within 2 minutes in most patients.
Children
Sugammadex is approved in pediatric patients aged 2 years and older at the 2 mg/kg (moderate block) and 4 mg/kg (deep block) doses. The same end points for recovery apply. The 16 mg/kg dose for immediate reversal is not recommended in children because data are insufficient in this population. In children below 2 years of age and in infants, sugammadex use is not routinely recommended outside specialist pediatric anesthesia centers and research protocols.
Elderly
No dose adjustment is required on the basis of age alone. Elderly patients often have reduced renal function and may experience a slightly longer recovery time, but they respond to the same weight-based doses as younger adults. Quantitative monitoring is particularly important in the elderly because the consequences of residual neuromuscular block — including postoperative pulmonary complications — are more severe in this population.
Obese Patients
Dosing is based on actual (total) body weight, not ideal or lean body weight. Under-dosing based on ideal body weight is a common pitfall and is associated with incomplete reversal and re-paralysis in the recovery room. In patients with a body mass index above 40 kg/m², doses above the capped product range should be calculated carefully and checked with the pharmacy.
Renal Impairment
In mild to moderate renal impairment (creatinine clearance 30–80 ml/min) the same doses as in adults with normal renal function are used, but the anesthesia team will typically extend monitoring to confirm sustained recovery. In severe renal impairment (creatinine clearance below 30 ml/min) or patients on dialysis, sugammadex Aguettant is not recommended because the sugammadex-rocuronium complex accumulates and long-term safety data are limited.
| Indication | Adults | Children (2–17 y) | Time to TOF ≥ 0.9 |
|---|---|---|---|
| Moderate block (T2) | 2 mg/kg IV | 2 mg/kg IV | ~2 min |
| Deep block (PTC 1–2) | 4 mg/kg IV | 4 mg/kg IV | ~3 min |
| Immediate reversal after rocuronium 1.2 mg/kg | 16 mg/kg IV | Not recommended | ~2 min |
| Re-administration (same surgery) | 4 mg/kg IV (if recurrence after 2 mg/kg) or 16 mg/kg IV (if after 4 mg/kg) | 4 mg/kg IV | ~3 min |
How Sugammadex Aguettant Is Administered
Sugammadex Aguettant is supplied as a ready-to-use clear to slightly yellow solution for injection in 2 ml and 5 ml pre-filled syringes containing 100 mg/ml. The dose is drawn up or dispensed from the syringe directly and injected rapidly (over approximately 10 seconds) into a free-flowing intravenous line through which compatible fluids are running. It can be diluted in 0.9% sodium chloride or 5% glucose for infusion, but single-injection administration is the standard approach and is reflected in all clinical trials supporting approval.
Missed Dose
Sugammadex Aguettant is not a drug that patients self-administer, so the concept of a "missed dose" does not apply in the usual sense. If sugammadex is omitted at the end of surgery and the patient shows signs of residual neuromuscular blockade (muscle weakness, poor cough, inability to sustain a head-lift for 5 seconds), the anesthesia team will administer it promptly to achieve full recovery. Continued mechanical ventilation and sedation may be required until recovery is confirmed.
Overdose
Overdose with sugammadex has been described in case reports up to 40 mg/kg without long-term sequelae. Acute toxicity studies in animals did not identify a specific toxic syndrome. Management is supportive: maintain the airway, monitor hemodynamics, and observe for possible hypersensitivity or bradycardia. Sugammadex is dialysable in severe renal impairment using a high-flux dialyzer, but dialysis is rarely required in the perioperative setting. A dose error should be documented and flagged in the patient's anesthesia record and in institutional quality systems.
What Are the Side Effects of Sugammadex Aguettant?
Most patients receiving sugammadex have no identifiable side effects beyond those expected from surgery and general anesthesia. The most frequent reactions reported in clinical trials are cough, airway complications on emergence, transient hypotension or hypertension, nausea, and vomiting. Clinically important but less frequent events are hypersensitivity reactions (including anaphylaxis), marked bradycardia, and recurrence of neuromuscular blockade. The anesthesia team monitors continuously for these events during and immediately after administration.
Adverse events associated with sugammadex have been characterized in more than 3,500 patients in sponsor-led clinical trials and in large real-world post-marketing experience since first approval in 2008. The overall incidence of drug-related adverse events is comparable to that observed with neostigmine-based reversal, although the type of events differs. Because sugammadex does not inhibit acetylcholinesterase, it is essentially free of the muscarinic effects (bradycardia, salivation, bronchoconstriction, nausea) that traditionally required concomitant glycopyrrolate or atropine. Conversely, a small number of events are specific to sugammadex, notably hypersensitivity and, occasionally, recurrence of block.
Very Common Side Effects
- No adverse reactions are classified as very common in the approved Summary of Product Characteristics for sugammadex
- The most frequently reported events in trials (cough, airway complications) fell into the "common" frequency category
Common Side Effects
- Cough
- Airway complications of anesthesia including bucking against the endotracheal tube
- Anesthetic complications such as abnormal movement during emergence
- Procedural hypotension
- Procedural hypertension
- Nausea and vomiting
- Procedural pain
Uncommon Side Effects
- Hypersensitivity including skin rash, flushing, erythema, urticaria, itching
- Light sedation or sleepiness (beyond that expected from anesthesia)
- Dysgeusia (altered taste)
- Recurrence of neuromuscular blockade, usually when a suboptimal dose was given
- Awareness of returning consciousness during recovery
Rare and Very Rare Side Effects
- Anaphylactic and anaphylactoid reactions, including bronchospasm and shock
- Marked bradycardia, occasionally progressing to cardiac arrest (reported within minutes of administration)
- Transient prolongation of prothrombin time and activated partial thromboplastin time (up to 1 hour)
- Angioedema
- Cardiovascular collapse in the setting of anaphylaxis
Reporting Adverse Reactions
Suspected adverse reactions should be reported to the national pharmacovigilance system in the country where the drug was administered. In the European Union, patients and healthcare professionals can report through the national regulatory authority website (for example, the UK's Yellow Card Scheme, France's ANSM, Germany's BfArM, or Sweden's Medical Products Agency). In the United States, the FDA MedWatch program accepts reports from patients and clinicians. Reporting helps regulators monitor the safety of medicines and protect future patients. Any hypersensitivity reaction should also be investigated with allergy referral and documented clearly in the patient's medical record.
Long-Term Safety Considerations
Because sugammadex is used as a single perioperative dose, long-term adverse effects are not expected in the usual sense. Pharmacovigilance data collected over more than a decade of worldwide use confirm the favorable safety profile, with no signal of delayed carcinogenicity, organ toxicity, or allergenic sensitization beyond what is already captured in the Summary of Product Characteristics. Ongoing research is examining whether quantitative neuromuscular monitoring combined with sugammadex reduces postoperative pulmonary complications compared with neostigmine-based reversal; early meta-analyses suggest a moderate but consistent benefit, particularly in high-risk populations.
How Should You Store Sugammadex Aguettant?
Sugammadex Aguettant is stored by the hospital pharmacy or operating theater, not by individual patients. It should be kept in the original pre-filled syringe, below 30°C, protected from light, and used within the approved shelf life printed on the carton. After opening or dilution, any unused solution must be discarded according to local hazardous-pharmaceutical waste procedures.
Correct storage is essential to guarantee the potency and safety of an intravenous medicine used in time-critical anesthesia emergencies. Sugammadex Aguettant is a robust molecule at pharmaceutical concentrations, but exposure to extreme temperatures, light, or prolonged standing after dilution can compromise the product. Because the drug is managed at the institutional level, individual patients do not handle storage decisions, but knowing the principles helps patients, caregivers, and ward staff recognize when a product should be considered out of specification.
General Storage Conditions
- Temperature: Store below 30°C. Do not freeze
- Light: Keep the pre-filled syringe in the outer carton to protect from light
- Integrity: Inspect each syringe before use. Use only clear, colorless to slightly yellow solutions without visible particles or discoloration
- Shelf life: Do not use after the expiry date printed on the carton and the syringe label. The expiry date refers to the last day of the stated month
In-Use and Diluted Solutions
When sugammadex Aguettant is diluted for infusion in 0.9% sodium chloride or 5% glucose, the diluted solution should ideally be used immediately. If dilution cannot be followed by immediate use, chemical and physical in-use stability has been demonstrated for up to 48 hours at 2–8°C. However, from a microbiological perspective, the solution should be used immediately unless dilution has taken place under validated aseptic conditions. Any unused diluted solution should be discarded at the end of the surgical list.
Keeping Medicines Safe
All unused medicines, pre-filled syringes, and disposable materials must be disposed of in accordance with local regulations for pharmaceutical and biohazard waste. Patients and the general public should never be offered loose injectable medicines; these products are strictly hospital-only and are tracked through the institutional pharmacy.
What Does Sugammadex Aguettant Contain?
Each ml of Sugammadex Aguettant solution for injection contains 100 mg of sugammadex (as sugammadex sodium). The excipients are water for injections, hydrochloric acid and/or sodium hydroxide for pH adjustment. The solution is sterile, essentially isotonic, and does not contain preservatives, lactose, sulfites, or latex.
Understanding the composition of a medicine helps patients and healthcare professionals anticipate potential issues such as allergy to inactive ingredients and compatibility with other intravenous fluids. Sugammadex Aguettant has a deliberately simple formulation that reflects the physicochemical stability of the active ingredient and the requirements of an intravenous single-use product used in emergency contexts.
Active Ingredient
- Sugammadex (as sugammadex sodium): 100 mg per ml of solution. The molecule is a modified gamma-cyclodextrin with eight negatively charged carboxyl groups at its outer rim, giving the compound its high water solubility and negligible oral absorption
Excipients (Inactive Ingredients)
- Water for injections: Pharmaceutical-grade sterile water as the vehicle
- Hydrochloric acid (3.7%) and/or sodium hydroxide: Used in small quantities to adjust the solution to a pH of approximately 7.0–8.0, which is optimal for intravenous administration
Presentation and Packaging
Sugammadex Aguettant is supplied in colorless, glass pre-filled syringes fitted with a plunger, Luer-lock connector, and tamper-evident cap. The product is available in the following presentations:
- 2 ml pre-filled syringe containing 200 mg of sugammadex
- 5 ml pre-filled syringe containing 500 mg of sugammadex
Cartons may contain one or multiple syringes for hospital pharmacy distribution. The pre-filled syringe presentation is designed to reduce the risk of dose calculation errors and to minimize preparation time in time-critical anesthesia emergencies, where every second of airway compromise matters.
Marketing Authorization Holder and Manufacturer
The marketing authorization holder for Sugammadex Aguettant in the European Union is Laboratoire Aguettant, based in Lyon, France. The product is manufactured under EU-GMP conditions at facilities inspected by ANSM and the European Medicines Agency. The reference product, Bridion, is produced by Merck Sharp & Dohme (MSD / Organon). Both products are interchangeable in clinical practice subject to local hospital formulary decisions.
Frequently Asked Questions About Sugammadex Aguettant
Medical References
This article is based on peer-reviewed medical research and international guidelines. All sources are evaluated according to the GRADE framework for evidence-based medicine.
- European Medicines Agency (EMA) (2022). Summary of Product Characteristics: Sugammadex Aguettant 100 mg/ml solution for injection. EMA Medicines Database Primary regulatory source for European Union marketing authorization, dosing, and contraindications.
- European Medicines Agency (EMA) (2019). Bridion (sugammadex) European Public Assessment Report (EPAR). EMA EPAR Bridion Reference product assessment used to support hybrid approval of Sugammadex Aguettant.
- U.S. Food and Drug Administration (FDA) (2023). Bridion (sugammadex) prescribing information. FDA Label Bridion United States label with detailed dosing and safety information, fully consistent with the EU SmPC for bioequivalent products.
- Blobner M, et al. (2010). "Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial." European Journal of Anaesthesiology. 27(10):874–881. doi:10.1097/EJA.0b013e32833d56b7 Pivotal randomized trial demonstrating faster and more complete recovery with sugammadex compared with neostigmine.
- Hristovska AM, Duch P, Allingstrup M, Afshari A (2017). "Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults." Cochrane Database of Systematic Reviews. Issue 8, Art. No. CD012763. doi:10.1002/14651858.CD012763 Cochrane systematic review of 41 randomized trials supporting the efficacy and favorable side-effect profile of sugammadex.
- Fuchs-Buder T, Romero CS, Lewald H, et al. (2023). "Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care." European Journal of Anaesthesiology. 40(2):82–94. doi:10.1097/EJA.0000000000001769 Current ESAIC clinical practice guideline on quantitative neuromuscular monitoring and pharmacological reversal.
- Thilen SR, Weigel WA, Todd MM, et al. (2023). "2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade." Anesthesiology. 138(1):13–41. doi:10.1097/ALN.0000000000004379 ASA guideline recommending quantitative monitoring and sugammadex as the preferred reversal agent for moderate to deep aminosteroid block.
- Min KC, Bondiskey P, Schulz V, et al. (2018). "Hypersensitivity incidence after sugammadex administration in healthy subjects: a randomised controlled trial." British Journal of Anaesthesia. 121(4):749–757. doi:10.1016/j.bja.2018.05.056 Prospective study characterizing hypersensitivity frequency and dose dependence for 4, 8, and 16 mg/kg sugammadex.
- Kheterpal S, Vaughn MT, Dubovoy TZ, et al. (2020). "Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications: A Multicenter Observational Study." Anesthesiology. 132(6):1371–1381. doi:10.1097/ALN.0000000000003256 Large real-world study associating sugammadex with a reduction in postoperative pulmonary complications.
- British National Formulary (BNF) / Joint Formulary Committee (2024). "Sugammadex — anaesthesia, other drugs used for." BNF Online. BNF Sugammadex Authoritative United Kingdom prescribing reference, updated in line with EMA and MHRA guidance.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in anesthesiology, pharmacology, and perioperative medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Anesthesiologists
Licensed specialist physicians in anesthesiology and intensive care medicine, with documented clinical experience in neuromuscular monitoring, perioperative pharmacology, and airway management.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing in anesthesia and critical care.
Researchers
Academic researchers with peer-reviewed publications on residual neuromuscular blockade, quantitative monitoring, and postoperative pulmonary complications.
Medical Review
Independent review panel that verifies all content against international medical guidelines, ESAIC, ASA, EMA, and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, ESAIC, ASA, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in anesthesiology, pharmacology, internal medicine, and clinical research.